Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University spinout Argonaut Therapeutics is developing cancer drugs that reprogram cancer cells to undergo the body's natural process of cell death, shrinking tumours.

Drugs Oleksii Fedorenko - Shutterstock

The company will focus on treatments for colorectal cancer and lymphoma.

Argonaut has raised seed funding from investment company Oxford Sciences Innovation to develop and test a set of drug candidates, as well as biomarkers that allow physicians to determine which patients are most likely to respond well to the new drugs.

Argonaut founder Professor Nick La Thangue is Chair of Cancer Biology at the University of Oxford. He said: 'Cancer drugs are relatively ineffective in as many as 70% of patients, in part due to genetic variations between patients. The demand for precision, personalised medicine is increasing. It is a cost-effective way of detecting disease earlier and it allows us to tailor therapies for each patient.

Read more